Publications by authors named "D M Nanus"
Article Synopsis
- Advanced urothelial cancer displays significant genetic diversity and involves complex interactions between internal and external mutagens, which contributes to its deadly nature.
- The study revealed that APOBEC3-induced mutations occur early during tumor development, while chemotherapy leads to a surge of later mutations, with both processes affecting the structure of extrachromosomal DNA.
- Findings emphasized the role of circular ecDNA in the development of treatment resistance, specifically through CCND1 amplifications, highlighting key mechanisms that can inform future cancer therapies.
Subsequently to the publication of the above article, an interested reader drew to the authors' attention that, for the immunostaining experiments shown in Fig. 3C on p. 1195, the 'NEP' and 'PTX' panels contained overlapping data, such that data which were intended to show the results of differently performed experiments had apparently been derived from the same original source.
View Article and Find Full Text PDFUnlabelled: Circulating tumor cells (CTCs) captured from the bloodstream of patients with solid tumors have the potential to accelerate precision oncology by providing insight into tumor biology, disease progression and response to treatment. However, their potential is hampered by the lack of standardized CTC enrichment platforms across tumor types. EpCAM-based CTC enrichment, the most commonly used platform, is limited by EpCAM downregulation during metastasis and the low EpCAM expression in certain tumor types, including the highly prevalent and lethal NSCLC.
View Article and Find Full Text PDFArticle Synopsis
- Cancer of unknown primary (CUP) poses a major challenge, being a leading cause of cancer death despite better diagnostic methods.
- A novel genomic analysis using whole-exome sequencing (WES) and RNA sequencing (RNA-seq) helped tailor treatment for a patient with a history of multiple tumors and fast progression on chemotherapy.
- The approach resulted in significant improvements across all metastatic sites and underscores the need for personalized genomic profiling to effectively manage CUP and identify tumor origins.
Purpose: HOXB13 is an androgen receptor (AR) coregulator specifically expressed in cells of prostatic lineage. We sought to associate circulating tumor cell (CTC) HOXB13 expression with outcomes in men with mCRPC treated with abiraterone or enzalutamide.
Experimental Design: We conducted a retrospective analysis of the multicenter prospective PROPHECY trial of mCRPC men (NCT02269982, n = 118) treated with abiraterone/enzalutamide.